Home Home Home Inbox Home Search

Event

Extended Pharmacodynamic and Immunomodulatory Activity of the MAPKAP Kinase II (MK2) Inhibitor MMI-0100 Demonstrated in a Phase 1 Lipopolysaccharide (LPS) Challenge Study Conducted in Subjects Who Smoke [Board No. 909]

Location: Board no. 909
Session Type: RAPiD: Rapid Abstract Poster Discussion Session
Sunday
May
20
9:15 AM
11:15 AM

Speaker(s)/Author(s)

Grant Nicholson

PhD
Respiratory Clinical Trials

Alyssa Panitch

PhD
University of California, Davis

Caryn Peterson

BSc
Moerae Matrix

Andrew Luber

Pharm.D.
Moerae Matrix

Robert Gerwien

PhD
Moerae Matrix

Cynthia Lander

PhD
Moerae Matrix

Brian Leaker

MD
Heart Lungs Center

View Abstract

Extended Pharmacodynamic and Immunomodulatory Activity of the MAPKAP Kinase II (MK2) Inhibitor MMI-0100 Demonstrated in a Phase 1 Lipopolysaccharide (LPS) Challenge Study Conducted in Subjects Who Smoke

Parent Sessions

  • A21 - CLINICAL AND MECHANISTIC STUDIES OF LUNG FIBROSIS...
    05-20-2018 9:15 AM - 11:15 AM
    • Home Home Home Inbox Home Search